Home > Insider Trading > Filing (0000899243-17-026997)

Filing Details

Accession Number:: 0000899243-17-026997
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2017-11-20 17:28:27
Reporting Period:: 2017-11-20

Accepted Time:: 2017-11-20 17:28:27
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1501697	Arsanis Inc.	ASNS	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1254452	Jay Michael Ross	C/O Sv Health Investors One Boston Place Suite 3900, 201 Washington Street Boston MA 02108		Yes	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2017-11-20	19,128	$0.00	19,128	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2017-11-20	404	$0.00	19,532	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2017-11-20	247,010	$0.00	266,542	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2017-11-20	5,219	$0.00	271,761	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2017-11-20	322,102	$0.00	593,863	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2017-11-20	6,806	$0.00	600,669	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2017-11-20	111,955	$0.00	712,624	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2017-11-20	2,365	$0.00	714,989	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2017-11-20	202,915	$0.00	917,904	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2017-11-20	4,288	$0.00	922,192	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2017-11-20	431,980	$0.00	1,354,172	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2017-11-20	14,789	$0.00	1,368,961	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2017-11-20	483,448	$10.00	1,852,409	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2017-11-20	16,552	$10.00	1,868,961	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A-1 Convertible Preferred Stock	Disposition	2017-11-20	65,287	$0.00	19,128	$0.00
Common Stock	Series A-1 Convertible Preferred Stock	Disposition	2017-11-20	1,380	$0.00	404	$0.00
Common Stock	Series A-2 Convertible Preferred Stock	Disposition	2017-11-20	690,259	$0.00	247,010	$0.00
Common Stock	Series A-2 Convertible Preferred Stock	Disposition	2017-11-20	14,587	$0.00	5,219	$0.00
Common Stock	Series B Convertible Preferred Stock	Disposition	2017-11-20	721,402	$0.00	322,102	$0.00
Common Stock	Series B Convertible Preferred Stock	Disposition	2017-11-20	15,246	$0.00	6,806	$0.00
Common Stock	Series C Convertible Preferred Stock	Disposition	2017-11-20	224,665	$0.00	111,955	$0.00
Common Stock	Series C Convertible Preferred Stock	Disposition	2017-11-20	4,747	$0.00	2,365	$0.00
Common Stock	Series D Convertible Preferred Stock	Disposition	2017-11-20	692,552	$0.00	202,915	$0.00
Common Stock	Series D Convertible Preferred Stock	Disposition	2017-11-20	14,635	$0.00	4,288	$0.00
Common Stock	Series D Convertible Preferred Stock	Disposition	2017-11-20	1,474,348	$0.00	431,980	$0.00
Common Stock	Series D Convertible Preferred Stock	Disposition	2017-11-20	50,477	$0.00	14,789	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Footnotes

The Series A-1 Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-1 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date.
The Series A-2 Convertible Preferred Stock converted into Common Stock on a 0.35785-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date.
The Series B Convertible Preferred Stock converted into Common Stock on a 0.44650-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date.
The Series C Convertible Preferred Stock converted into Common Stock on a 0.49832-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date.
The Series D Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date.
These shares are owned directly by SV Life Sciences Fund V, L.P. ("SVLS V LP"). SV Life Sciences Fund V (GP), LP ("SVLS V GP") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. The reporting person, a member of the investment committee of SVLSF V, LLC, may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. ("SVLS V SPP"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. The reporting person, a member of the investment committee of SVLSF V, LLC, may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
These shares are owned directly by SV Life Sciences Fund VI, L.P. ("SVLS VI LP"). SV Life Sciences Fund VI (GP), LP ("SVLS VI GP") is the general partner of SVLS VI LP. The general partner of SVLS VI GP is SVLSF VI, LLC. The reporting person, a member of the investment committee of SVLSF VI, LLC, may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
These shares are owned directly by SV Life Sciences Fund VI Strategic Partners, L.P. ("SVLS VI SPP"). SVLS VI GP is the general partner of SVLS VI SPP. The general partner of SVLS VI GP is SVLSF VI, LLC. The reporting person, a member of the investment committee of SVLSF VI, LLC, may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.